During our industry postdoc session, Dr. Nabet will share his journey from a Ph.D. trainee to a postdoc to a principal scientist in Genentech. Dr. Nabet will also share information for people interested in joining the industry as a postdoc. Check out Dr. Nabet

Bio

Dr. Nabet completed his Ph.D. at the University of Pennsylvania in 2017, training as an experimental cancer biologist focusing on the mechanisms underlying tumor-stroma interactions. As a postdoctoral fellow at Stanford University, he focused on translational and computational analyses. During his Ph.D. and postdoc training, Dr. Nabet published multiple papers on Cell. After joining Genentech in 2020, he has 4 papers at Genentech, including one co-first author paper in Cancer Cell.

Dr. Nabet’s research focus is primarily on non-small cell lung cancer and small cell lung cancer. Dr. Nabet’s team utilizes multi-omics to profile patient tumors from large randomized clinical trials to understand the molecular features and tumor subtypes that drive response or resistance to immune checkpoint inhibition.